TrialPath
Asthma · Philadelphia

Asthma clinical trials in Philadelphia

6 recruiting asthma studies within range of Philadelphia. Click any trial for full eligibility criteria and contact info.

SMART Implementation-Effectiveness Trial 1

NCT07137923 · Asthma in Children
Recruiting

While single maintenance and reliever therapy (SMART) has been the preferred management strategy for Step 3 and 4 (moderate/severe) asthma management since the 2020 NIH asthma guideline updates, adoption of SMART has not been rigorously assessed. This study will test electronic medical record clinical decision support and education implementation strategies (CDS+) to increase adoption of SMART in pediatric primary care. This is the first of two related records.

PhaseNA
TypeInterventional
Age5 Years – 18 Years
WherePhiladelphia, Pennsylvania, United States
SponsorChildren's Hospital of Philadelphia
▾Tap for details
Apply

A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)

NCT07782996 · Asthma
Recruiting

The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.

PhasePhase 3
TypeInterventional
Age12 Years – 80 Years
WhereSan Diego, California, United States + 12 more
SponsorGlaxoSmithKline
▾Tap for details
Apply

SMART Implementation-Effectiveness Trial 2

NCT07138027 · Asthma in Children
Recruiting

While single maintenance and reliever therapy (SMART) has been the preferred management strategy for Step 3 and 4 (moderate/severe) asthma management since the 2020 NIH asthma guideline updates, adoption of SMART has not been rigorously assessed. This study will test population health management (PHM; asthma community health worker, asthma nurse care manager) implementation strategies building on electronic medical record clinical decision support and education implementation strategies (CDS+), to increase adoption of SMART. This is the second of two related records.

PhaseNA
TypeInterventional
Age5 Years – 18 Years
WherePhiladelphia, Pennsylvania, United States
SponsorChildren's Hospital of Philadelphia
▾Tap for details
Apply

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

NCT06979323 · Asthma
Recruiting

Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.

PhasePhase 3
TypeInterventional
Age18 Years
WhereBrooksville, Florida, United States + 49 more
SponsorGlaxoSmithKline
▾Tap for details
Apply

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654 · Eosinophilic Asthma
Recruiting

This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereLancaster, California, United States + 80 more
SponsorKymera Therapeutics, Inc.
▾Tap for details
Apply

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263 · Asthma
Recruiting

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereBakersfield, California, United States + 222 more
SponsorAstraZeneca
▾Tap for details
Apply